Clinical trials: Diabetic Complication
Diabetic Macular Edema, Diabetic Retinopathy
Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy
The purpose of this study is to determine the safety and tolerability of MS-R001 at escalating doses in patients with diabetic macular edema secondary to diabetic retinopathy
- Trial name
- NCT00401115
- Testing
- MS-R001 (rapamycin)
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Santen Inc.
Diabetic Foot
BE Study of Metformin GSK 500mg
A randomized, balanced, open label, crossover, two period, two treatment, two sequence, single dose, oral bioequivalence study under fasting condition. It is a pivotal study.
- Trial name
- BA/BE 173/11 (NCT01710527)
- Testing
- Metformin 500mg, Glucophage 500mg
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetic Foot
The Pharmacokinetic Study of WH-1 Ointment in Subjects With Chronic Diabetic Foot Ulcers
The objective of this study is to evaluate the systemic exposures of WH-1 ointment which includes Salvigenin and Asiaticoside A in subjects with chronic diabetic foot ulcers following topical application of WH-1.
- Trial name
- NCT02353273
- Testing
- WH-1 ointment
- Where
- Taiwan
- Volunteers
- 12 people
- Sponsor
- Oneness Biotech Co., Ltd.
Diabetic Nephropathies
This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)
The main objective of this trial is the safety and tolerability of 3 multiple rising oral doses of BI 685509 over 28 days in male and female patients with Diabetic Nephropathy (DN) as adjunctive to Angiotensin Converting Enzyme…
- Trial name
- NCT03165227
- Testing
- BI 685509
- Where
- 35 sites in United States, Belgium and 3 more
- Volunteers
- 75 people
- Sponsor
- Boehringer Ingelheim
Polyneuropathy, Diabetic
Phase IV Trial to Evaluate Efficacy of Alpha-Lipoic Acid in Treating Symptomatic Diabetic Polyneuropathy in Egypt
The purpose of the study is to find out whether ALA is effective and safe for treating Egyptian diabetic patients with symptomatic polyneuropathy.
- Trial name
- MIRACLE-ALA (NCT05813496)
- Testing
- Alpha-Lipoic Acid (ALA)
- Where
- 5 sites in Egypt
- Volunteers
- 430 people
- Sponsor
- Eva Pharma